LifeTech Scientific Corporation released its monthly return for the period ended 31 March 2026, confirming a stable capital structure and minor adjustments in employee share option schemes.

The company’s authorised share capital remained at 40.00 billion ordinary shares with a par value of USD 0.00000125 each, representing total authorised capital of USD 50,000—unchanged from the previous month.

Issued share capital was steady at 4.63 billion ordinary shares, with no treasury shares outstanding or created during the month. Consequently, the public float continued to meet the Main Board’s 25% minimum threshold.

Share-based incentives saw limited movement: • Under one option scheme, 80,000 options lapsed, reducing outstanding options to 25.41 million. • A second scheme recorded 270,000 lapsed options, leaving 283.41 million outstanding. No new shares were issued and no treasury shares were transferred as a result of option exercises, resulting in zero equity dilution for the month.

The company reported no activity in warrants, convertible securities, or other share-issuance arrangements, and confirmed full compliance with Hong Kong listing regulations and all relevant legal requirements.